Stockscreener 앱 받기
9.1592
4.88%
-0.4708
전일 마감가:
$9.63
열려 있는:
$9.31
하루 거래량:
65,286
Relative Volume:
0.07
시가총액:
$151.45K
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-4.18%
1개월 성능:
-94.86%
6개월 성능:
-99.62%
1년 성능:
-99.92%
1일 변동 폭
$9.12
$9.65
1주일 범위
$9.12
$11.68
52주 변동 폭
$6.71
$17,908.00
Cero Therapeutics Holdings Inc Stock (CERO) Company Profile
명칭
Cero Therapeutics Holdings Inc
전화
650-407-2376
주소
201 HASKINS WAY, SOUTH SAN FRANCISCO
CERO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CERO
Cero Therapeutics Holdings Inc
|
9.1507 | 151.45K | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.77 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
536.93 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
547.01 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.70 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cero Therapeutics Holdings Inc 주식(CERO)의 최신 뉴스
Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga
Aurora Cannabis, Bitdeer Technologies Group And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Dow Dips Around 300 Points As Israel-Iran Conflict Escalates: Investor Sentiment Declines, Fear & Greed Index Moves To 'Neutral' Zone - Benzinga
CERo Therapeutics stock soars after FDA grants Orphan Drug Designation By Investing.com - Investing.com India
CERo Therapeutics stock soars after FDA grants Orphan Drug Designation - Investing.com
Sector Update: Health Care - MarketScreener
Crude Oil Rises Sharply; Jabil Earnings Top Views - Benzinga
CERo Therapeutics (CERO) Stock Explodes Over 200% in a Landmark Trading Day - Daily Chhattisgarh News
CERO Trading Halted Due to Market Volatility | CERO Stock News - GuruFocus
CERo Therapeutics Says CER-1236 Gets FDA Orphan Drug Designation in Acute Myeloid Leukemia - marketscreener.com
US Stocks Lower; Retail Sales Decline In May - Benzinga
CERO Trading Resumes: Key Developments and Insights | CERO Stock News - GuruFocus
What's Going On With Cero Therapeutics Stock Tuesday? - Benzinga
Cero Therapeutics announces FDA ODD granted to CER-1236 - TipRanks
CERo Therapeutics Gains FDA Orphan Drug Designation - TipRanks
CERo Therapeutics Gets Orphan Drug Status For CER-1236 In Acute Myeloid Leukemia - Nasdaq
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug - GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML) - Yahoo
FDA Grants Orphan Status to CeroTherapeutics' Acute Myeloid Leukemia Drug | CERO Stock News - GuruFocus
Cero Therapeutics treatment of leukemia granted orphan designation - TipRanks
CERo Therapeutics Conducts Reverse Stock Split to Meet Nasdaq Requirements - TipRanks
CERo Therapeutics announces 1-for-20 reverse stock split effective June 13 - MSN
Trading Halted for CERO; Anticipated Announcement Pending | CERO Stock News - GuruFocus
Cero Therapeutics announces 1-for-20 reverse stock split - Yahoo Finance
CERO Announces One-for-Twenty Reverse Stock Split | CERO Stock N - GuruFocus
CERo Therapeutics to implement 1-for-20 reverse stock split By Investing.com - Investing.com South Africa
CERo Therapeutics to implement 1-for-20 reverse stock split - Investing.com Australia
CERo Therapeutics Announces Reverse Stock Split - TipRanks
CERo Therapeutics Holdings, Inc. Announces One-for-Twenty Reverse Stock Split Effective June 13, 2025 - Nasdaq
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split - GlobeNewswire
CERo Therapeutics Sets Major 1:20 Reverse Split, Shares Consolidate 95% Next Week - Stock Titan
CERo Therapeutics issues additional Series D stock By Investing.com - Investing.com South Africa
CERo Therapeutics Completes Series D Stock Issuance - TipRanks
CERO Expands Series D Preferred Stock Offering to Raise Capital - GuruFocus
CERo Therapeutics issues additional Series D stock - Investing.com
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing - The Manila Times
CERo Therapeutics Holdings, Inc. Issues Additional Series D Preferred Stock Shares to Institutional Investors for Up to $8 Million - Nasdaq
CERo Therapeutics Lands $3M Series D Extension as CAR-T Cancer Trial Shows Promise - Stock Titan
CERo Therapeutics regains Nasdaq compliance - MSN
Cero announces two granted U.S. patents, European patent application allowance - Yahoo Finance
CERo Therapeutics secures key patents for cancer therapy By Investing.com - Investing.com South Africa
CERo Therapeutics Expands Leadership with New Executive Roles - TipRanks
Maxim Group Maintains Buy Rating on CERo Therapeutics (CERO) - Insider Monkey
CERO Therapeutics Expands Patent Portfolio with New U.S. and Eur - GuruFocus
CERo Therapeutics secures key patents for cancer therapy - Investing.com Australia
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236 - The Globe and Mail
CERo Therapeutics Holds 18 Patents and Applications Expanding Immunotherapy Portfolio - Nasdaq
CERo Therapeutics Secures 18 Global Patents for Revolutionary Cancer-Fighting Cell Therapy Technology - Stock Titan
CERo Therapeutics Holdings, Inc. (CERO) Doses First Patient in CER-1236 CAR-T AML Trial - MSN
CERo Therapeutics (NASDAQ:CERO) Rating Lowered to “Hold” at D Boral Capital - Defense World
CERo Therapeutics (NASDAQ:CERO) Receives “Hold” Rating from D. Boral Capital - Defense World
Cero Therapeutics Holdings Inc (CERO) 재무 분석
Cero Therapeutics Holdings Inc (CERO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Cero Therapeutics Holdings Inc 주식 (CERO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| YK Bioventures Opportunities G | 10% Owner |
Dec 13 '24 |
Sale |
0.06 |
2,998,908 |
179,934 |
13,005,169 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 12 '24 |
Sale |
0.07 |
1,614,541 |
113,018 |
16,004,077 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 11 '24 |
Sale |
0.08 |
1,343,801 |
107,504 |
17,618,618 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 06 '24 |
Sale |
0.12 |
1,236,874 |
148,425 |
21,383,909 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 10 '24 |
Sale |
0.09 |
1,570,947 |
141,385 |
18,962,419 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 09 '24 |
Sale |
0.11 |
850,543 |
93,560 |
20,533,366 |
| SLOAN STUART M | 10% Owner |
Sep 25 '24 |
Sale |
0.10 |
532,486 |
55,538 |
21,067,956 |
| YK Bioventures Opportunities G | 10% Owner |
Oct 10 '24 |
Sale |
0.10 |
3,250,000 |
325,000 |
22,620,783 |
0.27%
0.53%
자본화:
|
볼륨(24시간):